Back and forth we go....it's perplexing to see how these studies go round and round with DMT's slowing progression / not slowing progression.
DMT's work best when progression is mainly driven by inflammation, rather than by neurodegeneration.
We need new ideas for DMT's that slow or prevent the neurodegeneration type of progression.
DMTs Ease SPMS Disability Early But Not Over Time
Continuing treatment not found to slow long-term disability progression
"Results showed that patients in the treatment group had lower EDSS scores at the index date, reflecting a lower degree of disability, and that these scores tended to remain lower over the course of follow-up.
However, scores generally increased for all patients over time, and the rate of disability progression was not significantly different in treated versus untreated patients. This meant that treated patients had less disability in the earlier stages of their disease, but treatment did not slow the progression of their disease at later stages.
“Non-treated SPMS patients have generally higher EDSS values than treated patients, suggesting a beneficial effect of DMTs in slowing disease accumulation at earlier stages of the progressive phase,” Pontieri said. “However, as patients get older, staying on DMTs does not seem to slow [disability progression].”
“While DMTs might be beneficial in SPMS patients at earlier stage of progression, their effect might fade away as patients get older, stressing the importance of earlier recognition and intervention of progressive transition,” the team concluded."
#ECTRIMS2022 – DMTs Ease SPMS Disability Early But Not Long | Continuing Treatment Won't Slow Long-term Disability Progression | Multiple Sclerosis News Today
DMT's work best when progression is mainly driven by inflammation, rather than by neurodegeneration.
We need new ideas for DMT's that slow or prevent the neurodegeneration type of progression.
DMTs Ease SPMS Disability Early But Not Over Time
Continuing treatment not found to slow long-term disability progression
"Results showed that patients in the treatment group had lower EDSS scores at the index date, reflecting a lower degree of disability, and that these scores tended to remain lower over the course of follow-up.
However, scores generally increased for all patients over time, and the rate of disability progression was not significantly different in treated versus untreated patients. This meant that treated patients had less disability in the earlier stages of their disease, but treatment did not slow the progression of their disease at later stages.
“Non-treated SPMS patients have generally higher EDSS values than treated patients, suggesting a beneficial effect of DMTs in slowing disease accumulation at earlier stages of the progressive phase,” Pontieri said. “However, as patients get older, staying on DMTs does not seem to slow [disability progression].”
“While DMTs might be beneficial in SPMS patients at earlier stage of progression, their effect might fade away as patients get older, stressing the importance of earlier recognition and intervention of progressive transition,” the team concluded."
#ECTRIMS2022 – DMTs Ease SPMS Disability Early But Not Long | Continuing Treatment Won't Slow Long-term Disability Progression | Multiple Sclerosis News Today
Comment